review-outlines-how-neural-and-endocrine-circuits-govern-cd8-t-cell-fate
Review Outlines How Neural and Endocrine Circuits Govern CD8 T Cell Fate

Review Outlines How Neural and Endocrine Circuits Govern CD8 T Cell Fate

A comprehensive review published in Biomarker Research shows that antitumor cytotoxic CD8⁺ T cell activity is regulated not only within the tumor microenvironment but also through multiscale autonomic neural circuits and endocrine axes. While cancer immunology has predominantly focused on local intercellular signaling within the tumor microenvironment, clinical observations linking chronic stress, sleep disruption, endocrine comorbidity, and circadian rhythms to immune checkpoint inhibitor outcomes indicate that systemic physiological circuits modulate cytotoxic T cell responses across distant anatomical compartments. CD8⁺ T cells act as central cytotoxic effectors of antitumor immunity, but tumor-infiltrating populations remain functionally heterogeneous, encompassing tumor-reactive, dysfunctional, and bystander states. Researchers Tian Cheng, Xintong Li, and colleagues synthesized evidence detailing how autonomic and sensory neural networks, along with systemic endocrine systems, coordinately govern CD8⁺ T cell priming, tissue trafficking, cellular metabolism, and exhaustion.

To evaluate these systemic pathways as actionable therapeutic targets, the authors formulated a four-part framework conceptualizing candidate pathways as neuro-endocrine immune checkpoints analogous to canonical checkpoints such as PD-1 or CTLA-4. Under this framework, a candidate pathway must meet four functional criteria: first, receptor abundance, cellular accessibility, or ligand exposure must selectively increase under tumor- or stress-associated conditions to amplify inhibitory signaling in CD8⁺ T cells; second, ligand-receptor engagement must initiate inhibitory cascades that impair T cell receptor signaling, effector functions, or metabolic fitness; third, tumors must actively exploit these pathways through aberrant innervation, hypothalamic-pituitary-adrenal axis hyperactivation, or localized hormone metabolism to build an immunosuppressive barrier; and fourth, pharmacological blockade must reverse T cell dysfunction and augment immune checkpoint inhibitor efficacy. Candidate nodes satisfying these criteria include the β1-adrenergic receptor, the calcitonin receptor-like receptor and receptor activity-modifying protein 1 complex, and the glucocorticoid receptor.

Sympathetic nervous system signaling operates as a major efferent arm of the systemic stress response, suppressing CD8⁺ T cell function through dual adrenergic receptor pathways. Chronic psychological or physiological stress drives sustained release of norepinephrine, which acts systemically via the circulation and locally through sympathetic nerve terminals infiltrating the tumor parenchyma. Norepinephrine binding to β2-adrenergic receptors activates a stimulatory Gαs, adenylyl cyclase, cyclic adenosine monophosphate, and protein kinase A signaling cascade in CD8⁺ T cells. This pathway attenuates T cell receptor-driven nuclear factor kappa B and activator protein 1 transcription, suppressing effector cytokine production and cytolytic capacity while restricting glucose transporter 1 membrane translocation and aerobic glycolysis. Simultaneously, norepinephrine induces interleukin-6 release from stromal cells, activating Janus kinase and signal transducer and activator of transcription 3 signaling in neighboring T cells to upregulate co-inhibitory receptors PD-1 and TIM-3.

The sympathetic regulatory landscape extends to the β1-adrenergic receptor, encoded by the ADRB1 gene, which exhausted CD8⁺ T cells selectively upregulate as they progress toward terminal exhaustion. Engagement of β1-adrenergic receptors triggers a cyclic adenosine monophosphate and cAMP-responsive element modulator pathway that represses cytokine production and cellular proliferation. Notably, β1-adrenergic receptor-positive exhausted T cells cluster around intratumoral sympathetic nerve fibers, creating a spatially restricted microenvironmental niche driven by local norepinephrine. Genetic deletion or pharmacological blockade of β1-adrenergic receptors limits progression to terminal exhaustion and, when combined with immune checkpoint inhibitors, enhances CD8⁺ T cell effector function and tumor control in preclinical melanoma and viral models. Preclinical studies with the non-selective beta-blocker propranolol demonstrated dual-receptor blockade that reversed T cell exhaustion and improved cytotoxic lymphocyte infiltration, corroborated by retrospective clinical cohort data associating beta-blocker use with improved overall survival in advanced melanoma.

Sensory nociceptors and the vagal-cholinergic axis also participate in systemic immune regulation, primarily through local peptide release and indirect myeloid programming. Transient receptor potential vanilloid 1-positive sensory neurons innervate tumor tissues and release calcitonin gene-related peptide and substance P in response to tumor-derived neurotrophic factors and cytokines. Calcitonin gene-related peptide binds the CLR/RAMP1 complex on CD8⁺ T cells, activating a Gαs-cAMP-PKA cascade that suppresses T-bet, downregulates CD25, and reduces interferon-γ and granzyme B synthesis to promote exhaustion. Substance P acts through neurokinin-1 receptors to augment antigen-elicited interferon-γ and dendritic cell-derived interleukin-12, though it also stimulates tumor cell proliferation. Conversely, vagal and cholinergic signaling operates largely through indirect mechanisms: acetylcholine engages α7 nicotinic acetylcholine receptors on macrophages to activate JAK2 and STAT3, suppressing tumor necrosis factor-α release and indirectly easing inflammatory exhaustion pressure on CD8⁺ T cells.

The endocrine system delivers sustained, long-range regulation of CD8⁺ T cell fate through circulating glucocorticoids released by the hypothalamic-pituitary-adrenal axis. Supraphysiological glucocorticoid concentrations, driven by chronic stress, bind the intracellular glucocorticoid receptor, prompting nuclear translocation and protein-protein transrepression of activator protein 1 and nuclear factor kappa B. This interaction abrogates transcription of interleukin-2, interferon-γ, and granzyme B, while transactivation via glucocorticoid response elements upregulates pro-apoptotic BIM and glucocorticoid-induced leucine zipper alongside glucose transporter 1 repression. In healthy human physiology, morning cortisol surges stimulate CXCR4 upregulation, causing an approximate 40 percent redistribution of circulating naive CD4⁺ and CD8⁺ T cells toward the bone marrow. In the tumor microenvironment, local glucocorticoid regeneration occurs when myeloid-expressed 11β-hydroxysteroid dehydrogenase type 1 converts inactive cortisone into active cortisol, forming a localized immunosuppressive barrier that can be targeted by pharmacological inhibitors.

Metabolic hormones profoundly alter CD8⁺ T cell bioenergetic fitness and functional persistence within nutrient-depleted tumor microenvironments. Insulin engages the insulin receptor to stimulate the IRS-PI3K-Akt-mTORC1 cascade, upregulating glucose transporter 1, sustaining aerobic glycolysis, and supporting clonal expansion. Adipokines also modulate systemic immunity: physiological leptin signaling through its receptor and the JAK-STAT3 pathway supports T cell activation, but chronic hyperleptinemia in obesity drives persistent STAT3 activation, leading to metabolic dysfunction, reduced interferon-γ, and elevated baseline PD-1 expression. In lipid-rich tumor environments, increased CD36 expression on CD8⁺ T cells enhances polyunsaturated fatty acid uptake, triggering lipid peroxidation, reactive oxygen species accumulation, glutathione depletion, and ferroptotic cell death. Preclinical pharmacological blockade of CD36 or inhibition of ferroptosis restores cytokine secretion, while metabolic modulators such as metformin activate AMP-activated protein kinase to reduce tumor hypoxia and protect infiltrating T cells from apoptosis.

Sex steroid hormones establish pronounced sexual dimorphism in antitumor immunity through diverging transcriptional and differentiation programs. Androgen receptor signaling in CD8⁺ T cells impairs stem-like self-renewal, upregulates ubiquitin-specific peptidase 18 to inhibit TAK1 and nuclear factor kappa B signaling, and promotes early growth response 4 transcription, driving functional dysfunction. In prostate cancer cells, androgen receptor activity represses the interferon-γ-induced CXCL9, CXCL10, and CXCL11 chemokine axis, thereby restricting cytotoxic T cell recruitment into the tumor parenchyma. Preclinical studies demonstrated that androgen receptor blockade improves T cell infiltration; however, three phase III trials evaluating androgen receptor blockade combined with immune checkpoint inhibitors—KEYNOTE-641, KEYNOTE-991, and IMbassador250—failed to improve overall survival or radiographic progression-free survival, underscoring that unselected patient populations and low baseline tumor immunogenicity impede checkpoint efficacy.

In contrast to androgen signaling, preclinical models indicate that estrogen receptor β signaling exerts cell-intrinsic supportive effects in CD8⁺ T cells, where T cell receptor activation induces receptor phosphorylation to amplify proximal signaling cascades through non-genomic mechanisms. Estrogen receptor α signaling in macrophages can conversely induce an immunosuppressive polarization phenotype that indirectly fosters CD8⁺ T cell exhaustion. Furthermore, progesterone receptor signaling on hormone receptor-positive breast cancer cells represses antigen processing machinery and surface major histocompatibility complex class I presentation, diminishing CD8⁺ T cell-mediated cytotoxicity. These divergent steroid actions highlight that shared steroid receptor classification does not confer equivalent checkpoint behavior, emphasizing the need to distinguish cell-intrinsic suppressive nodes from indirect microenvironmental effects.

The review concludes that overcoming immune checkpoint inhibitor resistance will require a shift toward systems-level oncology that accounts for convergent neuro-endocrine networks and circadian timing. Chronic stress concurrently triggers sympathetic tone and hypothalamic-pituitary-adrenal activation, subjecting CD8⁺ T cells to dual transcriptional repression via nuclear factor kappa B and activator protein 1 alongside compounded metabolic restriction. Although retrospective studies and circadian biological rhythms show temporal variation in immune cell distribution, clinical evidence does not support universal treatment windows for chrono-immunotherapy. The authors caution that existing mechanistic insights derive primarily from preclinical murine models, emphasizing that future translational success requires prospective, biomarker-stratified clinical trials that simultaneously target multiple neuro-endocrine checkpoints while accounting for patient chronotype, tissue context, and tumor immune profiles.

Subject of Research: Systemic neural and endocrine regulation of CD8⁺ T cell fate and immunotherapy resistance in cancer

Article Title: Multiscale neural and endocrine control of CD8⁺ T cell fate in cancer: from systemic physiology to local immune circuits

Article References: Cheng, T., Li, X., Yang, M., Gao, X., Li, H., & Liu, C. (2026). Multiscale neural and endocrine control of CD8⁺ T cell fate in cancer: from systemic physiology to local immune circuits. Biomarker Research, 14(1), Article 160. https://doi.org/10.1186/s40364-026-01040-9

Image Credits: AI Generated

DOI: 10.1186/s40364-026-01040-9

Keywords: CD8+ T cells, neuro-endocrine checkpoints, cancer neuroscience, sympathetic nervous system, norepinephrine, beta-adrenergic receptors, HPA axis, glucocorticoids, CGRP, vagus nerve, immune checkpoint inhibitors, T cell exhaustion, tumor microenvironment, androgen receptor, metabolic reprogramming, 11beta-HSD1, chrono-immunotherapy, immuno-oncology